A Pharmacist's Guide to PCSK9 Inhibitors:

Slides:

Advertisements

Similar presentations

Familial Hypercholesterolemia Foundation Patient Engagement and the Assessment of Value Cat Davis Ahmed Director of Outreach.

Advertisements

Figure 1: Questions included in questionnaire

Muscle pain with taking statin

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Tailoring Statin Therapy in Women

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

American Heart Association Scientific Sessions

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Understanding Statin Metabolism

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Counseling Patients About Germline BRCA Mutations

Diabetes Increases Risk of CVD

An Update on PCSK9 Inhibitors

Statins, HIV, and CVD.

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

My Approach to the Patient With Familial Hypercholesterolemia

PCSK9 Inhibitors and Cardiovascular Outcomes

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

A PCP's Guide to Dyslipidemia

Exploring Statin Intolerance

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Statins, HIV, and CVD.

Revisiting the Pharmacoeconomics of HF

Clinicians' Corner in Dyslipidemia

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Train-the-Trainer Cases

PCSK9 Inhibitors and Statin Intolerance

Achieving Lipid Targets With PCSK9 Inhibition

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Train-the-Trainer Cases

Train-the-Trainer Cases

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

A Pharmacist's Guide to PCSK9 Inhibitors:

Program Goals

Statistics

Hospital Discharges for Patients With CVD

Need for Care

Statins and Patient Groups

Diagnosing Statin Intolerance

Clinical Factors That Increase the Risk of Statin Intolerance

ACC Statin Intolerance App

Inadequate Statin Response

New Drug Class: PCSK9 Inhibitors

Bococizumab

Guidance for Use of PCSK9 Inhibitors

Familial Hypercholesterolemia (FH)

Pharmacoeconomic Implications

Cost Effectiveness Study

Cost Effectiveness – Future Considerations